Meropenem Venus (Meropenem Anhydrous)

Meropenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This disruption leads to loss of cell wall integrity, osmotic lysis, and rapid bacterial death. Its structure confers stability against many β‑lactamases, giving it activity against a wide range of Gram‑negative, Gram‑positive, and anaerobic pathogens.

The specific dose and infusion rate of Meropenem Venus are determined by the prescribing clinician based on infection severity, site, and patient factors such as renal function. Healthcare professionals calculate the appropriate regimen and adjust it as needed during therapy.

Safety of Meropenem Venus in pregnancy and lactation has not been fully established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss uncertainties with the patient and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the Meropenem Venus product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and import documentation.

Meropenem shares the broad‑spectrum activity of the carbapenem class but offers a slightly lower risk of inducing seizures compared with imipenem. It is stable against many β‑lactamases and provides reliable coverage for resistant Gram‑negative organisms, making it a preferred option when high‑grade resistance is suspected.

Meropenem Venus should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Once reconstituted, use the solution according to the manufacturer’s guidance and discard any unused portion after the specified time.

Meropenem Venus is supplied as an injectable solution for intravenous infusion. It is typically administered over 15‑30 minutes, depending on the prescribed dose and clinical protocol. Administration should be performed by qualified healthcare personnel in a setting equipped for sterile IV delivery.

The most serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Prompt recognition and management of these reactions are essential, and therapy should be discontinued if they occur.

Meropenem Venus is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving valproic acid, as the drug may reduce valproate levels.